<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Immunotherapy resistance &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/immunotherapy-resistance/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 10:04:37 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Immunotherapy resistance &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Moffitt Study Reveals Novel Mechanism Behind Immunotherapy Resistance</title>
		<link>https://bioengineer.org/moffitt-study-reveals-novel-mechanism-behind-immunotherapy-resistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 21 Aug 2025 21:43:10 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Anti-PD-1 therapy]]></category>
		<category><![CDATA[Immunotherapy resistance]]></category>
		<category><![CDATA[Inflammatory mediators in cancer]]></category>
		<category><![CDATA[Nerve injury-induced immunosuppression]]></category>
		<category><![CDATA[Tumor-nerve interaction]]></category>
		<guid isPermaLink="false">https://bioengineer.org/moffitt-study-reveals-novel-mechanism-behind-immunotherapy-resistance/</guid>

					<description><![CDATA[In a groundbreaking international collaboration, researchers from Moffitt Cancer Center, the Karolinska Institutet, and the University of Texas MD Anderson Cancer Center have uncovered an unexpected mechanism behind cancer’s resistance to immunotherapy. This novel insight reveals that certain tumors can actively injure adjacent nerves, triggering a cascade of inflammatory processes that ultimately diminish the effectiveness [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">256841</post-id>	</item>
		<item>
		<title>Cracking the Code of Cancer Drug Resistance</title>
		<link>https://bioengineer.org/cracking-the-code-of-cancer-drug-resistance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 29 Jul 2025 18:58:45 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Treatment Strategies]]></category>
		<category><![CDATA[Drug resistance mechanisms]]></category>
		<category><![CDATA[Immunotherapy resistance]]></category>
		<category><![CDATA[Multidrug Resistance in Cancer]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cracking-the-code-of-cancer-drug-resistance/</guid>

					<description><![CDATA[Cancer’s relentless capacity to outmaneuver treatment remains one of the most formidable obstacles in modern medicine. Among the most vexing manifestations of this challenge is multidrug resistance (MDR)—a phenomenon wherein tumors evolve the ability to withstand multiple anticancer agents that differ widely in their chemical compositions and therapeutic mechanisms. This sinister adaptability threatens to undermine [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">251792</post-id>	</item>
		<item>
		<title>Research Highlight: Basal Cell Carcinoma’s Low Immunogenicity Linked to Antigen Presentation Suppression from Its Cellular Origin</title>
		<link>https://bioengineer.org/research-highlight-basal-cell-carcinomas-low-immunogenicity-linked-to-antigen-presentation-suppression-from-its-cellular-origin/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 18 Apr 2025 15:46:46 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[Antigen presentation suppression]]></category>
		<category><![CDATA[Basal cell carcinoma immunogenicity]]></category>
		<category><![CDATA[Cancer immune evasion]]></category>
		<category><![CDATA[Epigenomic regulation in cancer]]></category>
		<category><![CDATA[Immunotherapy resistance]]></category>
		<guid isPermaLink="false">https://bioengineer.org/research-highlight-basal-cell-carcinomas-low-immunogenicity-linked-to-antigen-presentation-suppression-from-its-cellular-origin/</guid>

					<description><![CDATA[Basal cell carcinoma (BCC) sits at a fascinating crossroads in cancer biology: despite being the most mutated human cancer, it paradoxically exhibits remarkably low immunogenicity, rendering it resistant to many immune-based therapies. This perplexing phenomenon has puzzled oncologists and immunologists alike. A groundbreaking study led by Dr. Shawn Demehri at Massachusetts General Hospital, recently published [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">241522</post-id>	</item>
	</channel>
</rss>
